ATE457975T1 - Verbessertes syntheseschema für lacosamid - Google Patents

Verbessertes syntheseschema für lacosamid

Info

Publication number
ATE457975T1
ATE457975T1 AT05794396T AT05794396T ATE457975T1 AT E457975 T1 ATE457975 T1 AT E457975T1 AT 05794396 T AT05794396 T AT 05794396T AT 05794396 T AT05794396 T AT 05794396T AT E457975 T1 ATE457975 T1 AT E457975T1
Authority
AT
Austria
Prior art keywords
lacosamide
synthesis scheme
improved synthesis
compound
formula
Prior art date
Application number
AT05794396T
Other languages
English (en)
Inventor
Jens Riedner
Gavin Dunne
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of ATE457975T1 publication Critical patent/ATE457975T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • C07C273/1854—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas by reactions not involving the formation of the N-C(O)-N- moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05794396T 2004-10-02 2005-09-30 Verbessertes syntheseschema für lacosamid ATE457975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023556A EP1642889A1 (de) 2004-10-02 2004-10-02 Verbessertes Syntheseschema für Lacosamid
PCT/EP2005/010603 WO2006037574A1 (en) 2004-10-02 2005-09-30 Improved synthesis scheme for lacosamide

Publications (1)

Publication Number Publication Date
ATE457975T1 true ATE457975T1 (de) 2010-03-15

Family

ID=34926827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05794396T ATE457975T1 (de) 2004-10-02 2005-09-30 Verbessertes syntheseschema für lacosamid

Country Status (24)

Country Link
US (2) US7884134B2 (de)
EP (2) EP1642889A1 (de)
JP (1) JP5128281B2 (de)
KR (1) KR101246169B1 (de)
CN (2) CN101928230B (de)
AT (1) ATE457975T1 (de)
AU (1) AU2005291456B2 (de)
BR (1) BRPI0516735B8 (de)
CA (1) CA2570598C (de)
CY (1) CY1109994T1 (de)
DE (1) DE602005019437D1 (de)
DK (1) DK1799635T3 (de)
EA (1) EA012588B1 (de)
ES (1) ES2341470T3 (de)
HR (1) HRP20100239T1 (de)
IL (1) IL180479A (de)
MX (1) MX2007001253A (de)
NO (1) NO336765B1 (de)
NZ (1) NZ552076A (de)
PL (1) PL1799635T3 (de)
SI (1) SI1799635T1 (de)
UA (1) UA95600C2 (de)
WO (1) WO2006037574A1 (de)
ZA (1) ZA200610000B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327744T1 (de) 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US8191500B2 (en) 2005-11-24 2012-06-05 Kronoplus Technical Ag Coating device comprising flowing coating material for smooth or structured surfaces
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US8093426B2 (en) 2007-12-04 2012-01-10 Ranbaxy Laboratories Limited Intermediate compounds and their use in preparation of lacosamide
EP2297092A1 (de) 2008-05-28 2011-03-23 Pliva Hrvatska D.O.O. Polymorphe und amorphe formen von lacosamid und amorphe zusammensetzungen
KR101755548B1 (ko) * 2008-11-07 2017-07-07 유씨비 파르마 게엠베하 아미노산 유도체의 제조 방법
DE102008059155A1 (de) 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
CN101591300B (zh) * 2009-02-19 2011-05-04 成都伊诺达博医药科技有限公司 合成拉考沙胺的新方法
US20100240926A1 (en) * 2009-03-18 2010-09-23 Pliva Hrvatska D.O.O. Process for preparing (r)-n-benzyl-2-(benyloxycarbonylamino)-3-methoxypropionamide
US8440861B2 (en) 2009-08-06 2013-05-14 Medichem, S.A. Solid forms of an N-(phenylmethyl)propanamide derivative and processes of preparation
CN102020589B (zh) * 2009-09-19 2013-11-06 浙江九洲药业股份有限公司 一种氨基甲酸叔丁酯衍生物及其制备方法和应用
JP5564570B2 (ja) * 2009-09-25 2014-07-30 カディラ・ヘルスケア・リミテッド ラコサミドおよびその中間体の調製方法
EP2501674A2 (de) * 2009-11-19 2012-09-26 Ranbaxy Laboratories Limited Verfahren für die zubereitung von polymorphen formen von lacosamid
IT1398044B1 (it) * 2010-01-29 2013-02-07 Archimica Srl Processo per la preparazione della lacosamide
EP2528891A2 (de) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Verfahren zur reduzierung von unreinheiten in lacosamid
US8829226B2 (en) 2010-02-06 2014-09-09 Zhejiang Jiuzhou Pharmaceutical Co., Ltd Lacosamide intermediate compound, preparation method thereof and use thereof
CN102146048B (zh) * 2010-02-06 2013-11-13 浙江九洲药业股份有限公司 拉科酰胺中间体化合物及其制备方法和应用
WO2011095995A1 (en) 2010-02-08 2011-08-11 Natco Pharma Limited A process for the preparation of lacosamide
US8907132B2 (en) 2010-02-09 2014-12-09 Msn Laboratories Private Limited Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide
WO2011130615A2 (en) * 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
US20130123537A1 (en) * 2010-05-17 2013-05-16 K a s s Narayan Garimella Process for the preparation of lacosamide
WO2011158194A1 (en) 2010-06-15 2011-12-22 Medichem, S.A. Enzymatic resolution of racemic (2r,s)-2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide
EP2399901A1 (de) * 2010-06-23 2011-12-28 Archimica GmbH Zwischenprodukt zur Herstellung von Lacosamid und Verfahren zu dessen Herstellung und Umwandlung zu Lacosamid
US20130102811A1 (en) * 2010-07-02 2013-04-25 Sun Pharmaceutical Industries Ltd Process for the preparation of lacosamide
WO2012014226A1 (en) 2010-07-27 2012-02-02 Indoco Remedies Limited Process for preparation of lacosamide and some n-benzyl-propanamide intermediate derivatives
WO2012041986A1 (en) 2010-10-01 2012-04-05 Ucb Pharma Gmbh Process for the preparation of amino acid derivatives
ES2619403T3 (es) * 2010-10-19 2017-06-26 Euticals Gmbh Proceso para producir lacosamida
EP2487152A1 (de) 2010-11-17 2012-08-15 UCB Pharma GmbH Verfahren zur Herstellung von Lacosamide mit der Razematspaltung von O-methyl-DL-Serin
GB201020026D0 (en) 2010-11-25 2011-01-12 Cambrex Karlskoga Ab New process
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
CN102320993B (zh) * 2011-07-13 2013-11-27 石家庄四药有限公司 一种制备(r)-2-叔丁氧羰基氨基-3-甲氧基丙酸的方法
WO2013024383A1 (en) * 2011-08-12 2013-02-21 Alembic Pharmaceuticals Limited An improved process for the preparation of lacosamide
CA2847285C (en) 2011-08-29 2019-10-01 Signa S.A. De C.V. Processes for the preparation of (r)-2-acetamido-n-benzyl-3-methoxypropionamide and intermediates thereof
WO2013072933A2 (en) * 2011-10-03 2013-05-23 Glenmark Generics Limited Process for preparation of 2-acetamido-n-benzyl-3-methoxypropionamide
EP2776388A4 (de) 2011-11-10 2015-07-08 Davuluri Ramamohan Rao Verfahren zur herstellung von (r-)n-benzyl-2-acetamido-3-methoxypropionamid
MX341754B (es) 2011-11-15 2016-09-02 Sanofi Aventis Deutschland Proceso para la produccion de 2-(acetilamino)-n'-bencil-3-metoxipr opanamidas n-sustituidas.
US8748660B2 (en) 2012-07-09 2014-06-10 Council Of Scientific & Industrial Research Process for the synthesis of antiepileptic drug lacosamide
CN102816083B (zh) * 2012-07-30 2015-09-23 永光制药有限公司 拉科酰胺的制备方法
GB201219627D0 (en) 2012-11-01 2012-12-12 Cambrex Karlskoga Ab New process
WO2014155264A1 (en) 2013-03-25 2014-10-02 Jubilant Life Sciences Limited Process for the preparation of lacosamide using novel intermediates
CN103342655A (zh) * 2013-07-02 2013-10-09 扬州大学 取代乙二酮双苯胺希夫碱合成取代酰胺的新方法
KR101578979B1 (ko) * 2013-11-08 2015-12-18 에스티팜 주식회사 라코사마이드의 제조방법
CA2958283A1 (en) 2014-08-28 2016-03-03 RAO, Davuluri Ramamohan Improved process for the preparation of lacosamide and its novel intermediate
WO2016039393A1 (ja) * 2014-09-10 2016-03-17 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
CN104761465B (zh) * 2015-03-18 2017-05-31 四川同晟生物医药有限公司 一种拉科酰胺的制备方法
CN106699595B (zh) * 2015-07-21 2019-04-12 上海医药集团股份有限公司 一种拉科酰胺制备方法
CN106699605B (zh) * 2015-07-21 2019-08-20 上海医药集团股份有限公司 一种拉科酰胺中间体的甲基化方法
IN2015CH05001A (de) 2015-09-18 2015-10-16 Divis Lab Ltd
EP3659997A1 (de) 2015-11-13 2020-06-03 API Corporation Verfahren zur herstellung von lacosamid und zwischenprodukt davon
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
US9718765B1 (en) 2016-06-21 2017-08-01 Sci Pharmtech, Inc. Process for preparation of optically pure N-substituted-3-methoxypropionic acid derivatives
WO2018060781A1 (en) * 2016-09-28 2018-04-05 Unichem Laboratories Ltd An improved process for the preparation of lacosamide
CN106811492B (zh) * 2017-01-18 2019-11-01 长兴制药股份有限公司 一种拉科酰胺的制备方法
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
KR20190081386A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
CN110320291A (zh) * 2019-06-21 2019-10-11 山东省药学科学院 一种hplc法定量检测拉考沙胺注射液含量的方法
JP2022072636A (ja) * 2020-10-30 2022-05-17 住友化学株式会社 アミド化合物の製造方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5129456A (en) * 1974-08-30 1976-03-12 Tanabe Seiyaku Co Kogakukatsusei oo benjiruserinjudotai no seiho
JPS62132849A (ja) * 1985-12-04 1987-06-16 Toray Ind Inc Ｄ−またはＬ−Ｎ−ｔ−ブトキシカルボニル−Ｏ−ベンジルセリンの製造方法
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
PT1038522E (pt) 1996-03-15 2004-10-29 Res Corp Technologies Inc Derivados enantiomericos anticonvulsivos de aminoacidos
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
JP3996671B2 (ja) * 1997-07-09 2007-10-24 タマ化学工業株式会社 Ｎ−アルコキシカルボニル化、ｎ−アルケニルオキシカルボニル化またはｎ−アリールアルコキシカルボニル化されたアミノ酸類の製造方法
DK1311256T3 (da) * 2000-08-17 2005-11-28 Teva Pharma Anvendelse af derivater af valproinsyreamider og 2-valproinsyreamider til behandling eller forebyggelse af smerter og/eller hovedpinelidelser
ATE327744T1 (de) * 2001-03-20 2006-06-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen bei der behandlung von nicht-neuropathischem entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ES2285227T3 (es) * 2002-08-05 2007-11-16 Eli Lilly And Company Arilbenzodiazepinas sustituidas con piperazina.
US7794987B2 (en) * 2003-12-02 2010-09-14 Ucb Pharma Gmbh Method for treating central neuropathic pain
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
PL1781276T3 (pl) * 2004-08-27 2010-11-30 Ucb Pharma Gmbh Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EA019757B1 (ru) * 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
EP2468261A1 (de) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
EP2646001A2 (de) * 2010-12-02 2013-10-09 UCB Pharma GmbH Formulierung von lacosamid

Also Published As

Publication number Publication date
US20110130350A1 (en) 2011-06-02
KR101246169B1 (ko) 2013-03-21
WO2006037574A1 (en) 2006-04-13
MX2007001253A (es) 2008-10-02
ZA200610000B (en) 2007-08-29
KR20070057778A (ko) 2007-06-07
EA012588B1 (ru) 2009-10-30
EP1799635A1 (de) 2007-06-27
CA2570598A1 (en) 2006-04-13
JP2008514669A (ja) 2008-05-08
AU2005291456B2 (en) 2011-02-24
CN1989102A (zh) 2007-06-27
IL180479A (en) 2011-09-27
CA2570598C (en) 2013-12-17
US20080027137A1 (en) 2008-01-31
ES2341470T3 (es) 2010-06-21
CY1109994T1 (el) 2014-09-10
SI1799635T1 (sl) 2010-06-30
CN101928230A (zh) 2010-12-29
US7884134B2 (en) 2011-02-08
CN101928230B (zh) 2012-11-07
PL1799635T3 (pl) 2010-10-29
DE602005019437D1 (de) 2010-04-01
BRPI0516735B1 (pt) 2021-01-12
NO20072250L (no) 2007-04-30
NZ552076A (en) 2010-09-30
IL180479A0 (en) 2007-06-03
BRPI0516735A (pt) 2008-09-23
UA95600C2 (en) 2011-08-25
EP1642889A1 (de) 2006-04-05
BRPI0516735B8 (pt) 2021-05-25
US8809585B2 (en) 2014-08-19
EP1799635B1 (de) 2010-02-17
AU2005291456A1 (en) 2006-04-13
DK1799635T3 (da) 2010-05-17
NO336765B1 (no) 2015-10-26
CN1989102B (zh) 2011-04-20
HRP20100239T1 (hr) 2010-06-30
JP5128281B2 (ja) 2013-01-23
EA200700746A1 (ru) 2007-08-31

Similar Documents

Publication Publication Date Title
DK1799635T3 (da) Forbedret synteseskema for lacosamid
ATE480517T1 (de) Verfahren zur herstellung und reinigung von 2- hydrocarbyl-3,3-bis(4-hydroxyaryl-phthalimidin- monomeren
EA200702413A1 (ru) Способ получения 1-алкил-3-фенилурацилов
CY1110411T1 (el) Μεθοδος για την παραγωγη 3-οξο-πρεγν-4-ενο-21,17-καρβολακτονων μεσω της οξειδωσης 17-(3-υδροξυπροπυλο)-3,17-διυδροξυανδροστανιων ανευ μεταλλου
MX2009001816A (es) Procedimiento para la produccion de acido d,l-2-hidroxi-4-alquilti o butirico.
DE60205241D1 (de) Synthese von cannabinoiden
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
CY1107101T1 (el) Μεθοδος συνθεσης παραγωγων της 1,3-διϋδρο-2h-3-βενζαζεπιν-2-ονης και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης με φαρμακευτικως αποδεκτο οξυ
EA201000464A1 (ru) Способ получения очищенного синтез-газа из синтез-газа, содержащего следовые количества примеси сернистых соединений, с помощью металлорганической структуры
EA200900008A1 (ru) Новые хиральные промежуточные продукты, способ их получения и их применение в производстве толтеродина, фезотеродина или их активных метаболитов
CR8936A (es) Proceso para la sintesis de indoles n-alquilatados c-2, c-3 sustituidos utiles como inhibidores cpla2
IL177431A0 (en) New process for the synthesis of substituted alpha-aminoindan derivatives
EA200870038A1 (ru) Способ получения аминов
ATE423764T1 (de) Verfahren zur herstellung von hydrazon-derivaten
AR054874A1 (es) Metodo para producir un derivado de 5- hidroxi -1-alquilpirazol
ATE399757T1 (de) Neues verfahren zur herstellung von nitrooxyderivaten von paracetamol
EA200600542A1 (ru) Способ для производства thip
ATE469141T1 (de) Verfahren zur herstellung von substituierten thiophensulfonylisocyanaten
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
ATE529413T1 (de) Verfahren zur synthese von aryloxydiaminopyrimidinen
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
ATE425959T1 (de) Verfahren zur herstellung von amino- oder hydroxybenzonitrilen
EA200970203A1 (ru) Новый способ получения эфира 3-амино-5-фтор-4-диалкоксипентановой кислоты
UA96281C2 (ru) Способ получения сульфонамидов и промежуточных соединений

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1799635

Country of ref document: EP